Literature DB >> 16691119

Lewy bodies in progressive supranuclear palsy represent an independent disease process.

Hirotake Uchikado1, Anthony DelleDonne, Zeshan Ahmed, Dennis W Dickson.   

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy characterized by Parkinsonism, vertical gaze palsy, and early falls. Lewy bodies (LBs) are detected in approximately 10% of PSP cases, but there is little information on the relationship of LBs to tau pathology. We determined the frequency of LBs in a large series of autopsy-confirmed cases of PSP and studied the density and distribution of LBs, including Parkinson disease stage, in cases with LBs (PSP/LBD). PSP/LBD was compared with pure LB disease (LBD), including assessment of neuronal loss in key brainstem nuclei. Immunohistochemistry for alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%). One case had multiple system atrophy in addition to PSP and was excluded from further study along with 2 PSP/LBD cases with concurrent Alzheimer disease. The 29 cases of PSP/LBD were compared with 30 cases of PSP and 24 cases of LBD. The age, sex, brain weight, Braak neurofibrillary tangle (NFT) stage, as well as counts of NFTs and senile plaques were not different among PSP, LBD, and PSP/LBD, but disease duration was longer in LBD. The Parkinson disease stage was similar, but the density of LBs in most subcortical nuclei tended to be greater in LBD than in PSP/LBD. In contrast, substantia nigra neuronal loss was greater in PSP/LBD than both PSP and LBD. Double immunostaining demonstrated alpha-synuclein and tau in different neurons with few exceptions. The findings suggest that LBs in PSP are similar in distribution to those in LBD and independent of tau pathology. The greater density of LBs in LBD compared with PSP/LBD may be the result of longer disease duration in LBD, whereas greater neuronal loss in the substantia nigra in PSP/LBD may be the result of vulnerability of this brain region to both disease processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691119     DOI: 10.1097/01.jnen.0000218449.17073.43

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  19 in total

1.  Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.

Authors:  Hirotake Uchikado; Wen-Lang Lin; Michael W DeLucia; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-07       Impact factor: 3.685

2.  Diffuse Lewy Body Disease and Alzheimer Disease: Neuropathologic Phenotype Associated With the PSEN1 p.A396T Mutation.

Authors:  Dibson D Gondim; Adrian Oblak; Jill R Murrell; Rose Richardson; Francine Epperson; Owen A Ross; Bernardino Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  2019-07-01       Impact factor: 3.685

3.  Expanding the spectrum of neuronal pathology in multiple system atrophy.

Authors:  Matthew D Cykowski; Elizabeth A Coon; Suzanne Z Powell; Sarah M Jenkins; Eduardo E Benarroch; Phillip A Low; Ann M Schmeichel; Joseph E Parisi
Journal:  Brain       Date:  2015-05-16       Impact factor: 13.501

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

5.  Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project.

Authors:  Elizabeth E Blue; Joshua C Bis; Michael O Dorschner; Debby W Tsuang; Sandra M Barral; Gary Beecham; Jennifer E Below; William S Bush; Mariusz Butkiewicz; Carlos Cruchaga; Anita DeStefano; Lindsay A Farrer; Alison Goate; Jonathan Haines; Jim Jaworski; Gyungah Jun; Brian Kunkle; Amanda Kuzma; Jenny J Lee; Kathryn L Lunetta; Yiyi Ma; Eden Martin; Adam Naj; Alejandro Q Nato; Patrick Navas; Hiep Nguyen; Christiane Reitz; Dolly Reyes; William Salerno; Gerard D Schellenberg; Sudha Seshadri; Harkirat Sohi; Timothy A Thornton; Otto Valadares; Cornelia van Duijn; Badri N Vardarajan; Li-San Wang; Eric Boerwinkle; Josée Dupuis; Margaret A Pericak-Vance; Richard Mayeux; Ellen M Wijsman
Journal:  Dement Geriatr Cogn Disord       Date:  2018-02-27       Impact factor: 2.959

6.  Progressive supranuclear palsy: progression and survival.

Authors:  Julieta E Arena; Stephen D Weigand; Jennifer L Whitwell; Anhar Hassan; Scott D Eggers; Günter U Höglinger; Irene Litvan; Keith A Josephs
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

Review 7.  Neuropathology of non-Alzheimer degenerative disorders.

Authors:  Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2009-08-25

8.  Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy.

Authors:  Kenichi Oshima; Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2008-12-20

9.  Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology.

Authors:  Heather B Rigby; Brittany N Dugger; Joseph G Hentz; Charles H Adler; Thomas G Beach; Holly A Shill; Erika Driver-Dunckley; Marwan N Sabbagh; Lucia I Sue; John N Caviness
Journal:  Mov Disord Clin Pract       Date:  2014-10-29

10.  Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.

Authors:  Sireesha Manne; Naveen Kondru; Monica Hepker; Huajun Jin; Vellareddy Anantharam; Mechelle Lewis; Xuemei Huang; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.